Kornimate/medical-research-clean huggingface dataset:
yogurt probiotic bacteria on relieving young children acute gastroenteritis

Conditions: Acute Gastroenteritis

Summary: the goal of this clinical trial is to test the effect of mothers' application of yogurt probiotic bacteria on relieving their young children's acute gastroenteritis in children had two to five years old. the main hypothesis is children with acute gastroenteritis who receive yogurt probiotic bacteria exhibit less diarrhea, vomiting and dehydration than those who don't.the study subjects were divided into two equal groups (probiotic study group and control group).


Eligibility criteria:
inclusion criteria: * newly admitted children with no or some dehydration and with acute gastroenteritis. exclusion criteria: * bloody watery diarrhea

Keywords: yogurt probiotic bacteria young children gastroenteritis
can008 biomarker cd95 ligand and cpg2 methylation in chinese patients with glioblastoma

Conditions: Glioblastoma

Summary: this study was conducted on the post-operative tumor tissues from 62 gbm patients. 20 slices are necessary for all the cd95 and cpg2 test in the central lab by the methods of immunisation and dna methylation.


Eligibility criteria:
inclusion criteria: * chinese nationality * no limits on gender and age * first diagnosed gbm * brain tumor tissue cytological diagnosis of glioblastoma (gbm, pleomorphic glioblastoma, who level iv) exclusion criteria: * other types of glioma by histological diagnosis * tumor tissue not eligible for the central laboratory testing standard * no enough tumor tissue for the central laboratory test
efficacy of peri-neural platelet rich plasma injection in treatment of chemotherapy induced peripheral neuropathy.

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: this study aims to show the efficacy and safety of ultra-sound guided peri-neural platelet rich injection in treatment of chemotherapy induced peripheral neuropathy.

this study is prospective, randomized, assessor blinded controlled trial. it is aims to study the effect of perineural platelet rich plasma injection in cancer patients with prepheral neuropathy despite of stoppage chemotherapy for 6 months and usage of medical treatment. ultrasound-guided prp injection will be performed after preparation of plasma obtained from the patient by using 10-19 mhz high frequency linear transducer to scan the superficial nerves.

Eligibility criteria:
inclusion criteria: * cancer patients with peripheral neuropathy confirmed by clinical evaluation and nerve conduction study despite of medical treatment exclusion criteria: patients with: * foot ulcers and / or amputation. * peripheral vascular disease. * uncontrolled diabetes * vertebral pathologies. * connective tissue diseases. * thyriod disorders, significant renal or hepatic dysfunction. * platelet dysfunction syndrome, critical thrombocytopenia. * septicemia and local infection at the site of the procedure. * systemic corticosteriod adminstiration or local injection at the suspected treatment site within the last month. * recent fever or illness. * hemoglobin level less than 10 g/dl, platelet count less than 105-109/l.
scintigraphic evaluation of contractile and coronary reserve in patients with ischemic cardiomyopathy

Conditions: Ischemic Cardiomyopathy

Summary: according to single-photon emission computed tomography, the left ventricular contractile and coronary flow reserve (cfr) will be assessed in patients with ischemic cardiomyopathy. according to these data, the criteria for predicting the effectiveness of complex surgical treatment of this pathology will be evaluated.

before surgical intervention, all patients pass routine clinical analyzes undergo coronary angiography and 2d echocardiography. some of patients in the icm-1 and icm-2 groups undergo stress echocardiography with dobutamine. coronary arteriography is performed using the axiom artis (siemens; erlangen, germany) and transthoracic two-dimensional doppler echocardiography (tte) with the acuson sequoia 512 (siemens; erlangen, germany)). besides, all of the icm-1 and icm-2 groups patients undergo myocardial perfusion imaging. standard two-day stress-rest imaging protocol is used. adenosine at a dosage of 140 mcg/kg/min (for 4 min) is used as a pharmaceutical stress agent. icm-1 group and control group for gbps undergo gated blood pool spect (gbps) at rest and during increasing doses of dobutamine (5/10/15 μg/kg/min) (n = 60) icm-2 group and control group for cfr undergo dynamic spect (n = 40). this investigation is combined with routine myocardial perfusion imaging so patients are not exposed to extra stress. than icm patients undergo surgical treatment of icm in different volume. all of them receive coronary bypass grafting (cabg); some patients undergo the left ventricular reconstruction and intervention on the mitral valve. in the early postoperative period (7-14 days), the icm-1 group undergo rest gbps and icm-2 group undergo dynamic spect by two-day protocol. all patients undergo tte too. after at least 12 month, all patients undergo tte to assess the presence of left ventricular (lv) remodeling.

Eligibility criteria:
inclusion criteria: а) for icm group: 1. history of myocardial infarction (mi) or revascularization (cabg or pci); 2. \> 75% stenosis of left main or proximal lad and/ or stenosis of \> 75% of ≥2 epicardial vessels (based on coronary angiography (ca) data); 3. lv ef \<40% and increase in lv volumes according to echocardiography (echo) b) for gbps control group 1. absence of obstructive coronary artery lesion; 2. absence of history of mi and revascularization. c) for cfr control group 1. presence of obstructive coronary artery lesion; 2. indications for coronary artery bypass grafting; exclusion criteria (for all groups): 1. presence of contraindications to the stress test with inotropic stimulation; 2. inflammatory myocardial diseases; 3. the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research; 4. life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).

Keywords: ischemic cardiomyopathy single photon emission computed tomography gated blood pool spect coronary flow reserve prognosis
modulation of heme oxygenase 1 by nizatidine and lisinopril in healthy subjects

Conditions: Gastroparesis

Summary: to assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (ho-1) protein concentration and activity compared to placebo in healthy subjects.

current therapeutic options for gastroparesis are limited to dietary modifications and pharmacological (i.e., prokinetic and symptomatic) agents. exciting and novel preliminary data from our programs demonstrate that (i) reduced expression of heme oxygenase 1 (ho-1) is responsible for loss of interstitial cells of cajal and delayed gastric emptying in non-obese diabetic (nod) mice, (ii) upregulation of (ho-1) reverses delayed gastric emptying in this model, perhaps by generating carbon monoxide (co), which has anti-apoptotic and cytoprotective actions, and may relax smooth muscle, and (iii) hemin upregulates ho-1 in humans. however, hemin is exorbitant and can only be administered intravenously. a large throughput screening assay uncovered that the histamine h2 receptor antagonist nizatidine and the ace inhibitor lisinopril upregulate ho-1 in human embryonic kidney (hek) cells. hence, this double-blind placebo-controlled study will randomly assign 24 healthy subjects to one of 4 arms, and ho-1 protein activity and concentration will be assessed.

Eligibility criteria:
inclusion criteria: * healthy subjects without clinical evidence of significant cardiovascular, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns * normal serum potassium and estimated glomerular filtration rate (egfr) \> 60 ml/minute * baseline systolic bp ≥ 110 mmhg * no known hypersensitivity to lisinopril or nizatidine * able to provide written informed consent before participating in the study * able to communicate adequately with the investigator and to comply with the requirements for the entire study. exclusion criteria: * pregnant * breast feeding * current smoker * symptoms of functional gi disorder as assessed by a validated questionnaire * previous history of peptic ulcer disease.
remote monitoring in cancer care: a platform study

Conditions: Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Lung Carcinoma; Malignant Digestive System Neoplasm; Malignant Solid Neoplasm

Summary: this study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms. this study may help researchers understand if wearing the device is a better tool than standard vital sign assessment tools done only while at the doctor's office or hospital, and if using the smartphone app is a better tool than standard assessment tools used while in the doctor's office or hospital.

primary objectives: i. develop patient-specific algorithms to predict the trajectory of cytokine release syndrome (crs) and or neurotoxicity and time to escalation of medical intervention is needed. (arm 1) ii. establish the validity for the use of mobile technology to assess neurologic symptoms remotely. (arm 1) iii. compare the time to escalation of potential medical intervention between remote monitoring (rm) and standard care (sc) based on retrospective analysis of clinical trial data. (arm 1) iv. establish the feasibility for the use of wearable device for continuous, remote monitoring of physiologic parameters by quantifying false alerts and downstream clinical actions. (arm 1) v. define the range of physiologic variables associated with receipt of radiation and chemotherapy. (arm 2) vi. correlate pros and physician rated ctcae to biologic parameters. (arm 2) vii. establish the feasibility for the use of wearable device for continuous, remote monitoring of physiologic parameters by quantifying false alerts and downstream clinical actions. (arm 2) outline: arm 1: patients undergoing car-t therapy use the biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks. arm 2: patients undergoing radiation therapy (rt) for head and neck, lung, or gastrointestinal cancers use the biofourmis wearable device(s) for 60 to 90 days after completion of rt. patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of rt, after completion of rt, 3 months after completion of rt, and 1 year after completion of rt. in addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.

Eligibility criteria:
inclusion criteria: * arm 1: age \>= 18 years * arm 1: provide written informed consent * arm 1: patients undergoing commercial car-t cell therapy in an outpatient setting * arm 2: age \>= 18 years * arm 2: provide written informed consent * arm 2: patients with a plan to undergo radiation therapy for lung, gastrointestinal, or head and neck cancer exclusion criteria: * arm 1: non-english speaking * arm 1: planned initiation of lymphodepleting chemotherapy in the inpatient setting * arm 2: non-english speaking
effect of aquatic exercise versus aerobic exercise on primary dysmenorrhea and quality of life in adolescent females

Conditions: Dysmenorrhea Primary

Summary: this study was conducted to determine the difference between impact of aerobic and aquatic exercise on primary dysmenorrhea and quality of life in adolescent girls.

dysmenorrhea manifests as painful menstrual flow it occurs in two forms primary and secondary. primary and secondary dysmenorrhea is painful menstruation occur without any gynecological disease it was conducted that prevalence of dysmenorrhea 74.6% and it was significantly more frequent in students from rural residence (shaimaa et al., 2018). there is only one previous study investigate effect of aquatic exercise on primary dysmenorrhea (rezvani et al., 2013). there are several previous studies investigate effect of aerobic ex , however non of the previous studies compared between effect of aerobic and aquatic exercise on primary dysmenorrhea and quality of life of adolescent girls .therefore this study was the first one which aimed to investigate the difference between effect of aerobic and aquatic exercise on primary dysmenorrhea and quality of life in adolescent girls.

Eligibility criteria:
inclusion criteria: * healthy, nonsmoking, virginal girls having moderate to severe primary dysmenorrhea (score on pain rating scale \> 3). * their ages ranged from 14 to 20 years * their body mass index (bmi) ranged from 18 to 25 kg/m2. * they haven't practice any sports at least one year exclusion criteria: * any musculoskeletal disorder. * cardio-respiratory disease. * diabetes, hypertension, or anemia. * adolescent girls who have utilized hormonal treatment in the six months prior to study commencement. * currently undergoing pharmacological therapy for menstrual pain management

Keywords: primary dysmenorrhea adolescent females aquatic exercise aerobic exercise pressure pain threshold quality of life
a study of hs-20094 in t2dm participants

Conditions: Type 2 Diabetes

Summary: this is a randomized, placebo and active-control, multiple-dose, phase iia trial. patients were randomly assigned to receive hs-20094 (12 patients), placebo (3 patients), or active control drug semaglutide injection (3 patients) in a 4:1:1 ratio to each of four dose cohorts of 5 mg, 10 mg, 15 mg, and 20 mg. hs-20094 and placebo were administered in a double-blind design by subcutaneous injection once a week for a total of four times, and the dose was gradually increased weekly (2.5-2.5-5-5 mg, 5-510-10 mg, 5-10-15-15 mg, 5-10-15-20 mg). the active control drug semaglutide was administered by open-label, titrated subcutaneous injection once a week for a total of four times, and the dose was increased gradually every week until 1.0 mg (0.25-0.5-0.5-1.0 mg). the primary study objective was to 1) evaluate the safety and tolerability of multiple subcutaneous injections of hs-20094 in subjects with type 2 diabetes mellitus (t2dm) with or without overweight or obesity;2) evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of multiple subcutaneous injections of hs-20094.


Eligibility criteria:
inclusion criteria: * male or female subjects,20-65 years of age at the time of signing informed consent. * type 2 diabetes mellitus diagnosed for at least 3 months before the screening visit. * treated with conventional lifestyle intervention and stable treatment with metformin ( ≥ 1000 mg/day) at least 3 months prior to screening hba1c 7.5-10%(both inclusive)at screening visit. exclusion criteria: * a history of type 1 diabetes, specific diabetes, or secondary diabetes. * presence of-clinically significant lab or ecg results that may affect the evaluation of the efficacy or safety of the study drug at screening visit. * acute or chronic pancreatitis at any time before screening, or serum lipase/amylase above the upper limit of normal at screening. * a history of grade 2 hypoglycemia(blood glucose 3.0 mmol/l)or grade 3 hypoglycemia(hypoglycemia with a serious event of consciousness and/or physical alteration requiring assistance from another person for recovery)within 6 months before screening. * diabetid ketoacidosis or hyperosmolar coma or lactic acidosis requiring hospitalization occurred within 6 months before screening. * severe infection such as diabetic foot infection, pneumonia, or sepsis within 30 days before screening. * uncontrollable hypertension. * history of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening. * any organ-system malignancies developed within 5 years except for cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix. * pregnant or lactating woman. * in the investigator's judgment, there were circumstances that affected subject safety or otherwise interfered with the evaluation of results.
pedcapnetz - community acquired pneumonia (cap) in childhood and adolescence

Conditions: Community-acquired Pneumonia

Summary: establishment of a study network and patient cohort for pediatric cap

the aim of the project is the development of a large pediatric cap patient cohort based on the established pedcapnetz pilot cohort. the main objective is to improve knowledge on etiology, epidemiology, diagnosis and management of pediatric cap in a developed country. pedcapnetz will enable the systematic and detailed characterization of pediatric cap cases on an epidemiological, clinical and biological level.

Eligibility criteria:
inclusion criteria: * age \< 18 * symptoms of an acute lower respiratory tract infection with radiological confirmed pneumonia via ultrasound or chest x-ray exclusion criteria: * hospitalization for any reason within the last 28 days * congenital or acquired immunodeficiency * concomitant respiratory disease with impaired mucociliary clearance such as cystic fibrosis, primary ciliary dyskinesia, tracheostomy or other severe lung disease including pulmonary tuberculosis, malignancy, and cytostatic therapy during past 28 days or neutropenia (\< 1000/µl) or relevant immunosuppressive treatment
a study to compare the use of ferric carboxymaltose with placebo in patients with chronic heart failure and iron deficiency

Conditions: Iron Deficiency; Chronic Heart Failure

Summary: the purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (iv) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.


Eligibility criteria:
inclusion criteria: * iron deficient subjects with stable chronic heart failure (chf) (nyha ii-iii) on optimal background therapy for chf * reduced left ventricular ejection fraction * capable of completing 6 minute walk test * at least 18 years of age and with written informed consent prior to any study specific procedures exclusion criteria: * erythropoietin stimulating agent (esa) use, iv iron therapy and/or blood transfusion in previous 6 weeks prior to randomisation * exercise training program(s) in the 3 months prior to screening or planned in the next 6 months * chronic liver disease and/or elevated liver enzymes * vitamin b12 and/or serum folate deficiency * subject is not using adequate contraceptive precautions during the study * body weight ≤ 35 kg * no other significant cardiac or general disorders that would compromise the ability to give informed consent and/or comply with study procedures
fucoidan assisted eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection; Intestinal Bacteria Flora Disturbance

Summary: the purpose of this study is to investigate whether the eradication rate of h.pylori will be improved when adding fucoidan to the duplex scheme combination of amoxicillin and vonoprazan, and to explore the effect of fucoidan on gastrointestinal flora of patients.

after being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. at week 0, patients who meet the eligibility requirement will be included in this simultaneous blind test. a total of 60 patients with hp infection were enrolled in this study. all patients were randomly divided into two groups according to the ratio of 1:1. group a was given vonoprazan 20mg bid, amoxicillin 1000mg tid, fucoidan 1000mg bid for 14 consecutive days; group b was given vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days. on the 10th and 14th days of treatment, the researchers will follow up the patients' adverse reactions and medication compliance. the feces of the subjects were collected one day before the treatment, and on the 14th and 44th days after the treatment; after 4 weeks of drug withdrawal, all subjects will be reexamined with 13c-ubt.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years old; 2. patients diagnosed as hp positive; 3. patients who have not received hp eradication treatment in the past, or who have failed in the early eradication but have not received eradication treatment within half a year; 4. voluntarily participate in this trial and sign the informed consent form. exclusion criteria: 1. allergic to the study drug (penicillin allergy, etc.); 2. patients with chronic gastritis and peptic ulcer; 3. patients who have received hp eradication treatment within half a year; 4. antibiotics and bismuth agents were used 4 weeks before the start of the study treatment, and histamine h2 receptor antagonists or ppis were used 2 weeks before the start of the study treatment; 5. use adrenocortical hormones, non steroidal anti-inflammatory drugs or anticoagulants; 6. history of esophageal or gastric surgery; 7. pregnant and lactating women; 8. suffering from serious accompanying diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease;

Keywords: helicobacter pylori infection eradication treatment amoxicillin vonoprazan fucoidan intestinal flora
insulin regulation of lipolysis and lipolysis proteins

Conditions: Obesity

Summary: these studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.

1. the investigators will determine whether impaired insulin-induced suppression of lipolysis (as measured by ic50) is related to the above mentioned lipolysis proteins in groups of volunteers known to vary widely with regards to abdominal adipocyte size and regulation of adipose tissue lipolysis. 2. the investigators will determine whether the improved insulin regulation of lipolysis resulting from treatment with the pparγ agonist pioglitazone, with or without weight loss, can be linked to specific changes in sets of pparγ-responsive adipocyte lipolysis proteins in ubo adults.

Eligibility criteria:
inclusion criteria: * men and women between the ages of 18 and 55. * women will be premenopausal * non obese adults bmi between 18-25 * obese bmi 30-38 exclusion criteria, pioglitazone package insert of contraindications for use: * initiation in patients with established new york heart associations (nyha) class iii or iv heart failure. * use in patients with known hypersensitivity to pioglitazone or any other component of actose.

Keywords: adipose tissue